• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Generics May Not Remain a "Cheaper Option," Study Finds

Article

The study, published in NEJM, found that in addition to supply chain and manufacturing problems, lack of competition may be adding to their costs.

Market forces are dramatically driving up the cost of some generic drugs, prompting U.S. investigations into the pricing of what should be cheap alternatives to brand-name medications.

New England Journal of Medicine

Generics that should cost pennies per dose have undergone radical increases in price in recent years, said Dr. Aaron Kesselheim, author of a new commentary in the , and director of the Program on Regulation, Therapeutics and Law at Brigham and Women's Hospital in Boston.

For example, the widely used broad-spectrum antibiotic doxycycline has increased from 6.3 cents to $3.36 per pill. And the long-established antidepressant drug clomipramine has increased from 22 cents to $8.32 per pill, Kesselheim noted in his commentary.

Supply chain and manufacturing problems have caused some of these price hikes, he said. But Kesselheim believes that other increases have resulted from too few companies making the generic versions of these drugs.

Read the original report on MedlinePlus: http://bit.ly/1xEh0x1

Related Videos
Screenshot of Adam Colborn, JD during an interview
dr ian neeland
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.